(History)
Classical cancer studies in the 1930s showed that coal tar applied to a rabbit's ear causes papillomas, followed by tumors. The active ingredients in coal tar were determined to be polycyclic aromatic hydrocarbons (PAHs) such as benzo [a] pyrene (BaP). The parent PAH at first was thought to be the carcinogen, and an enzyme that metabolized PAHs thought to be beneficial in detoxication (1) . It was subsequently shown that PAHs, metabolized to reactive intermediates, bind covalently to nucleic acids and proteins to form adducts (2) ; thus, the concept of "metabolic activation" by PAHmetabolizing enzymes was born.
Mammalian cell cultures were found to have BaP hydroxylase (aryl hydrocarbon hydroxylase) activity that becomes highly induced within 12-24 hours upon exposure to various PAHs (3). This paradigm for studying the response of cultured cells to PAH treatment has led to a wealth of knowledge concerning transcription, translation, and signal transduction pathways (4-6).
Some inbred mouse strains are "sensitive" to the PAH inducer, while others are not (7) . Breeding sensitive C57BL/6 (B6) with resistant DBA/2 (D2) mice revealed that resistance was inherited largely as an autosomal recessive trait (8) . When 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; dioxin) was realized to be at least 30,000 times more potent than PAHs as an inducer of BaP hydroxylase, B6 and D2 mice were treated with dioxin and the effective dose for 50% induction (ED 50 ) was shifted ~15-fold to the right in the resistant D2, compared to the sensitive B6 mouse (Fig. 1) . These data--proven, years later, when the genes were cloned--suggested that the Cyp1a1 gene, which encodes BaP hydroxylase, has an identical amino-acid sequence in both B6 and D2 mice; however, the Ahr gene, which encodes the AHR that regulates CYP1A1 induction, has amino-acid differences responsible for high-affinity (in B6) and poor-affinity (in D2) receptor that binds dioxin or PAHs (reviewed in Refs. 10, 11) . Mice having the high-affinity AHR (and therefore higher CYP1 levels in response to lower doses of PAHs) were subsequently shown to be more prone than mice having the poor-affinity AHR to PAH-induced cancers, mutagenesis, birth defects, uroporphyria, and toxicity of the liver, eye and ovary when the administered PAH is in direct contact with the target organ (4). In contrast, mice having the poor-affinity AHR were at greater risk than high-affinity-AHR mice to developing malignancy or toxicity--such as immunosuppression, immune-system malignancy, or toxic chemical depression of the bone marrow--when the target organ is distant from the incoming PAH.
This seeming paradox can be explained by PAH pharmacokinetics, called "first-pass elimination" kinetics (reviewed in Ref. 4 ).
PAH-induced CYP1 and cancer studies in humans
Following reports of the mouse high-affinity/low-affinity AHR paradigm and relationship of high-CYP1 inducibility and cancer (12), a CYP1-inducibility assay was developed in mitogen-activated PAH-treated human lymphocytes (which are transformed 55 h later into lymphoblasts) in culture (13) , and an association was shown between high-CYP1-inducibility and bronchogenic carcinoma (14) . Following improvements in the assay (15) , many labs have found that the distribution of CYP1 inducibility was generally skewed to the left (Fig. 2) , i.e. more individuals displayed low, and fewer showed high, CYP1 inducibility. Studying cigarette smokers, more than a dozen laboratories independently found correlations between the high-CYP1-inducibility phenotype and cancer of the lung, larynx or oral cavity (tissues in direct contact with cigarette smoke), compared with no correlation between the high-inducibility phenotype and cancer of the renal pelvis, ureter, or urinary bladder (tissues distant from incoming cigarette smoke) (reviewed in Ref. 10 ).
Do differences in AHR affinity, similar to those found in mice, exist in human populations?
From K d values in 115 unrelated subjects, a >12-fold variation in affinity of the human AHR was by guest on http://www.jbc.org/ Downloaded from 5 found (Fig. 3) , but no known AHR gene polymorphism explains this variation (17) . AHR-mediated induction of CYP1 enzymes can lead to genotoxicity, mutation and tumor initiation (6) . The AHR is also associated with tumor promotion (18) and enhanced oxidative stress (19) independent of CYP1 activity. It is thus possible that a "high-affinity-AHR" patient might develop cancer of the oral cavity or lung after only 20 or 40 pack-years of smoking, whereas a "poor-affinity-AHR" individual might never develop cancer even after more than 100 pack-years.
It should be noted that the human CYP1B1 gene discovery was relatively late (20) , compared to knowledge about the CYP1A1, CYP1A2 and AHR genes that had been developed over more than two decades. Before the CYP1B1 enzyme activity was characterized, CYP1A1 had been believed to be responsible for virtually all BaP hydroxylase activity. CYP1B1 is now known to share with CYP1A1 the PAH-inducible BaP hydroxylase activity (21) . is associated with increased risk of cigarette smoking-induced lung cancer, especially when combined with the glutathione S-transferase mu (GSTM1*0) null mutation (23) . An I462V mutation, often associated with the Msp I mutation, was reported to have increased BaP hydroxylase activity (23); however, two independent studies showed that cDNA-expressed BaP hydroxylase activity in vitro is not different between the CYP1A1*1 wild-type and CYP1A1*2A, *2B or *2C allelic products (24, 25) . Similar associations (between the CYP1A1*2 alleles and lung cancer in cigarette smokers) were found in other laboratories in Japan (26) (27) (28) 
AHR
The AHR is a ligand-activated transcription factor that controls several dozen genes (5, 11, 36), including up-regulation of all three CYP1 genes (6). Ligands for the AHR include dioxin, PAHs, polyhalogenated aromatic hydrocarbons, indoles and tryptophan-derived endogenous ligands, and benzoflavones found especially in cruciferous plants (37) . The AHR gene exists in all vertebrates, and even in Caenorhabditis elegans (11) . The AHR participates in cell-cycle control and apoptosis that is cell type-or tissue-specific (6). To date, at least nine mutations in and near the human AHR The Ahr(-/-) knockout mouse exhibits lowered viability and fertility and defects in liver development (41) (42) (43) . The Ahr(-/-) mouse lacks constitutive and inducible CYP1 expression, and is resistant to TCDD-induced toxicity (44), topical BaP-induced skin tumors (43) , and benzeneinduced hemotoxicity (45) . The Ahr(-/-) mouse generated in Japan (46) appears to have high constitutive CYP1A2 levels in liver but not lung.
Paradoxical effects of CYP1A1 and CYP1A2
Historically, the role of CYP1A1 in BaP-induced toxicity was demonstrated in the Hepa-1c1c7 hepatoma cell line. Mouse Hepa-1 cells retain several differentiated liver functions--including albumin synthesis, commonly lost in culture (4-6). BaP-treated Hepa-1 cells grew only rarely as resistant variants; such colonies were used to complement the "resistance" phenotype in other colonies, which led to the discovery of at least three complementation groups (5). These were ultimately defined as the genes encoding Cyp1a1, Ahr, and the AHR's dimerization partner, the AHR nuclear translocator, Arnt. Thus, CYP1A1 activates BaP to become toxic, and the AHR and ARNT are necessary for Cyp1a1 inducible expression; these experiments showed that CYP1A1 is a primary determinant for BaP toxicity. Since these experiments were conducted in hepatoma cells, it was presumed that hepatic CYP1A1 is likely to be responsible for BaP-mediated toxicity in the intact animal. (48) and Cyp1b1(-/-) (49) knockout mice are viable and able to reproduce. Cyp1a2(-/-) mice exhibit increased toxicity from drugs that are predominantly CYP1A2 substrates (48, 50) . When Cyp1a1(-/-) mice were given oral BaP (125 mg/kg/day), however, all Further paradoxical responses were observed with the food mutagens IQ and PhIP on DNA adducts in liver, kidney, mammary gland and colon (55) and the effect of PhIP on the incidence of several types of malignancies (56).
Cyp1a1(-/-) (47), Cyp1a2(-/-)
To our knowledge, the Cyp1b1(-/-) mouse has not shown any such inconsistent effects. As might be predicted from in vitro studies, the Cyp1b1(-/-) mouse exhibits increased protection against 7,12-dimethylbenzo[a]anthracene (DMBA)-induced lymphomas (49), DMBA-induced marrow toxicity and pre-leukemia (57) and dibenzo[a,l]pyrene-induced tumors (58) . Hence, if CYP1B1 is not present to activate these environmental chemicals, less toxicity or neoplasia is seen.
Thus, in the context of hepatoma cells or in vitro studies, CYP1A1 is the primary determinant of BaP-mediated toxicity and DNA adduct formation and CYP1A2 is the primary determinant of arylamine-mediated toxicity and DNA adduct formation, whereas in the context of the intact animal, CYP1A1 and CYP1A2 can be protective. This dual role has not been seen with CYP1B1.
What might explain this difference? In microsomes, 9000 x g supernatant (S9) fractions or Hepa-1 cells, an absence of, or loose coupling to, Phase II metabolizing enzymes (Fig. 4) would result in enhanced adduct formation, oxidative stress and toxicity. In gastrointestinal epithelial cells or hepatocytes, it is possible that CYP1A1 and CYP1A2 are tightly coupled, resulting in efficient by guest on http://www.jbc.org/ Downloaded from detoxication rather than increases in toxicity. In the genetic absence of CYP1A1 or CYP1A2, other oxidative enzymes--CYP1B1, CYP2 and prostaglandin H synthase for BaP (51); CYP2A and flavin-containing monooxygenases for arylamines (52)--are responsible for adduct formation and toxicity. In immune cells, it is possible that CYP1B1 is not tightly coupled to phase II metabolism, or Phase II metabolism is low or absent, resulting in enhanced BaP-DNA adduct formation and toxicity. An additional likely factor is CYP1 enzyme concentration: gastrointestinal and hepatic CYP1A1 and CYP1A2 are very high in the paradoxical systems described above, whereas CYP1B1 content, in relative terms, is not high in immune cells.
Therefore, in the intact animal the role of CYP1 in detoxication versus activation to cause toxicity is likely to depend on the subcellular content and location, the amount of Phase II metabolism, the degree of coupling to Phase II enzymes, and cell type-and tissue-specific context, as well as pharmacokinetics (route of administration, target organ) of the chemical under study. The notion that CYP1A1 is causative in PAH-mediated toxicity and carcinogenesis (or CYP1A2 causative in ABP-, IQ-or PhIP-mediated toxicity and malignancy) may not be warranted and, in fact, the contrary may be true. These findings underscore the difficulties in using data collected in vitro to extrapolate to the in vivo situation. In vitro data have been invaluable in helping determine the catalytic specificities of CYP1 enzymes; from this perspective, there can be little doubt that CYP1B1 and CYP1A1 represent major cellular activities toward PAH metabolism or that CYP1A2 carries out arylamine metabolism. Their roles in causing, preventing, or not participating in PAH-or arylamine-mediated toxicities, however, need further investigation in the intact animal.
Thus, we have come full-circle. There was a time when CYP1 enzymes were thought to be primarily beneficial because of detoxication (1) . Then, we all became convinced that CYP1 enzymes were detrimental in that they caused toxicity and cancer (2, 4, 10, 12, 59) . Now, it appears that, in all likelihood, evolution has provided animals with CYP1 enzymes which, on balance, are generally more protective than destructive during environmental insult.
Generation of "humanized" BAC-transgenic mouse lines
"Humanized" hCYP3A4 and hCYP2D6 mouse lines have been developed, in which these pharmacologically important human genes were added to the mouse genome; even without the orthologous mouse Cyp3a and Cyp2d genes removed, these lines have proven very useful for numerous pharmacological studies (60) . A mouse line containing a human AHR cDNA in place of the mouse Ahr gene has recently been reported (61). Humanized hCYP1A1, hCYP1A2, hCYP1B1 and hAHR mouse lines are now under development, in which the human gene replaces the mouse orthologous gene. Two or more human genes might also be combined in developing a mouse line.
Such increasingly "humanized" mouse lines will be important in future risk assessment studies of toxicity and carcinogenesis. by guest on 
